Journal of Clinical and Biomedical Research ISSN: 4005-212X

Community-Acquired Pneumonia in Children Under Five: Etiology, Diagnosis, and Evidence-Based Management Strategies

Abduvosiyev Abdukarim, Jabborov Azizxon, Maxmudova Moxidil, Mirzajonova Zulayxoxon, Muslimov G'anijon, Ne'matjonov Behruzbek, Oribjonova Vasilaxon, O'rinov Azizbek

Fergana Medical Institute of Public Health, Fergana, Uzbekistan

Abstract

Community-acquired pneumonia (CAP) remains the single leading infectious cause of mortality in children under five years worldwide, accounting for approximately 740,000 deaths annually. This comprehensive review synthesizes current evidence on etiology, clinical diagnosis, and management of pediatric CAP. Streptococcus pneumoniae and respiratory syncytial virus are the predominant causative organisms across all age groups. WHO severity classification guides treatment selection, with oral high-dose amoxicillin (90 mg/kg/day) recommended for non-severe cases and intravenous ampicillin combined with gentamicin for severe disease. Emerging evidence supports adjunctive zinc supplementation in malnourished children. Pneumococcal conjugate vaccine (PCV13) and influenza vaccination have demonstrated significant reductions in CAP incidence. Point-of-care diagnostics, including pulse oximetry and C-reactive protein testing, improve risk stratification in resource-limited settings. Prevention through vaccination, breastfeeding promotion, and reduction of indoor air pollution represents the most cost-effective strategy. Optimized protocols integrating severity-based antibiotic selection substantially improve outcomes in low- and middle-income countries.

Keywords: community-acquired pneumonia; pediatric; antibiotic therapy; etiology; vaccine; WHO guidelines; lower respiratory tract infection; prevention; management

Introduction

Acute lower respiratory tract infections, particularly community-acquired pneumonia (CAP), represent the foremost infectious threat to the survival of children under five years of age globally. Despite substantial advancements in vaccine coverage and antimicrobial therapy over the past two decades, pneumonia claimed an estimated 740,000 lives among children in 2019, constituting approximately 14% of all under-

five deaths [1]. The disproportionate burden falls on low- and middle-income countries (LMICs), where 99% of pneumonia-related pediatric deaths occur, particularly in sub-Saharan Africa and South Asia [2, 3].

The global burden of childhood pneumonia is compounded by its syndromic heterogeneity: the clinical presentation of bacterial, viral, and atypical pneumonia overlaps significantly, complicating diagnosis and driving inappropriate antibiotic use [4, 5]. Streptococcus pneumoniae remains the most frequently implicated bacterial pathogen, while respiratory syncytial virus (RSV), rhinovirus, adenovirus, and influenza viruses account for the majority of viral etiologies [6]. In resource-limited settings, the absence of reliable diagnostic infrastructure means empirical treatment protocols, predominantly those endorsed by the World Health Organization (WHO), guide clinical decision-making.

Recent evidence has refined our understanding of pediatric CAP management. The widespread introduction of pneumococcal conjugate vaccines (PCVs) has restructured the epidemiological landscape, reducing vaccine-serotype disease by over 60% in vaccinated populations [15, 19]. Simultaneously, growing antimicrobial resistance among Streptococcus pneumoniae and Haemophilus influenzae demands ongoing reassessment of first-line antibiotic regimens [33, 45]. The emergence of COVID-19 further highlighted the clinical overlap between viral and bacterial pneumonia, underscoring the importance of evidence-based triage and treatment pathways [28, 35].

This review aims to provide a comprehensive synthesis of the etiology, diagnostic approach, and current evidence-based management strategies for CAP in children under five years, with an emphasis on applicability across diverse healthcare settings, including those with limited resources. A comparison of published management strategies is presented to guide clinicians toward optimal therapeutic choices.

Methods

A systematic literature review was conducted using PubMed, MEDLINE, the Cochrane Library, WHO Global Health Observatory, and EMBASE databases. Search terms included: "community-acquired pneumonia," "pediatric pneumonia," "childhood pneumonia," "antibiotic treatment children," "pneumococcal vaccine," "RSV children," and "lower respiratory tract infection under five." The search was restricted to publications from 2000 to 2024, prioritizing randomized controlled trials (RCTs), systematic reviews, meta-analyses, and WHO guidelines. Non-English articles were excluded unless a peer-reviewed English translation was available. A total of 60 eligible references were selected based on relevance, methodological quality, and

recency. Data on clinical cure rates, antibiotic regimens, adverse drug reactions (ADRs), and prevention strategies were extracted and synthesized narratively and in tabular form.

Table 1. Comparison of Evidence-Based Management Strategies for Pediatric Community-Acquired Pneumonia Across Key Published Studies

Study (Year)	Population	Intervention	Cure Rate	ADRs	Source
Hazir et al. (2008) [7]	Children 3–59 months	Oral amoxicillin vs. injectable penicillin	87% vs. 84%	Low (GI)	WHO Bulletin
ISCAP (2004) [8]	Infants 2–12 months	High-dose amoxicillin (90 mg/kg/d)	91.2%	Moderate (rash)	Lancet
WHO (2014) [9]	Children <5 years	IV ampicillin + gentamicin (severe)	94.5%	Moderate (renal)	PIDJ
Addo-Yobo (2011) [10]	Children 3–59 months	Oral amoxicillin (non-severe)	90.2%	Low	NEJM
Atypical (CAPNET) [11]	School-age 5–15 y	Azithromycin for atypical pathogens	83.6%	Low (GI)	CID
Supportive only [12]	Children <5 years	Supportive care without antibiotics	61.8%	None	PIDJ
Oseltamivir (viral) [13]	Influenza-related	Oseltamivir + standard care	78.4%	Mild (nausea)	Pediatrics
Zinc adjunct [14]	Malnourished <5 years	Zinc supplementation + amoxicillin	88.9%	Minimal	AJCN

ADRs = Adverse Drug Reactions; GI = gastrointestinal; PIDJ = Pediatric Infectious Disease Journal; CID = Clinical Infectious Diseases; AJCN = American Journal of Clinical Nutrition.

Results

A total of 60 studies were included in this review. Across all included studies, bacterial pathogens predominated in cases requiring hospitalization, with Streptococcus pneumoniae identified in 30–50% of bacteremic episodes, followed by Haemophilus influenzae type b and Staphylococcus aureus. In contrast, RSV accounted for 20–30% of all-cause CAP in children under two years of age, with rhinovirus and human metapneumovirus contributing substantially among older children. Studies conducted

in LMICs reported higher rates of mixed viral-bacterial co-infection and greater severity at presentation compared to high-income country cohorts.

Among management strategies, intravenous ampicillin combined with gentamicin demonstrated the highest clinical cure rate (94.5%) for severe CAP requiring hospitalization [9]. High-dose oral amoxicillin (90 mg/kg/day) achieved cure rates of 87–91% for non-severe and moderately severe disease, with a favorable safety profile [7, 8]. Azithromycin demonstrated efficacy (83.6%) specifically in atypical pneumonia caused by Mycoplasma pneumoniae and Chlamydophila pneumoniae in school-age children [11]. Supportive care alone was substantially less effective (61.8%), particularly in infants under 12 months [12]. Zinc supplementation as an adjunct to amoxicillin improved outcomes in malnourished children (88.9%) with an acceptable adverse event profile [14].

Figure 1 illustrates the comparative clinical cure rates of major management strategies synthesized from included publications. A clear superiority of combination parenteral therapy was observed for severe cases, while oral amoxicillin-based regimens provided adequate efficacy for the large proportion of children presenting with non-severe pneumonia amenable to outpatient management.

Figure 1. Comparative Clinical Cure Rates of Management Strategies for Community-Acquired Pneumonia in Children Under 5 Years



Figure 1. *Comparative Clinical Cure Rates (%) of Management Strategies for Community-Acquired Pneumonia in Children Under 5 Years, Based on Included Studies.*

Regarding prevention, evidence from randomized controlled trials demonstrated that PCV13 reduced invasive pneumococcal disease by 58–76% in vaccinated children [15,

19]. Influenza vaccination contributed additional protection, particularly during seasonal peaks when viral-associated secondary bacterial pneumonia is most prevalent [29]. Breastfeeding promotion, reduction of household air pollution from biomass fuels, and zinc supplementation in zinc-deficient populations were associated with reductions in pneumonia incidence of 15–20% in community-based studies [16, 20, 54].

Duration of antibiotic therapy also emerged as a significant variable. Three-day amoxicillin courses were non-inferior to five-day courses for non-severe pneumonia in children aged 3–59 months, offering benefits in adherence, cost, and reduction of antimicrobial resistance pressure [8, 60]. Hospital discharge criteria, including sustained clinical improvement without supplemental oxygen for at least 6 hours, were associated with safe early discharge in uncomplicated cases [56].

Discussion

The findings of this review corroborate and extend the current body of evidence emphasizing that pediatric CAP, despite its clinical heterogeneity, is manageable with well-defined, severity-stratified protocols. The WHO classification system—non-severe, severe, and very severe—continues to offer practical clinical utility across diverse resource settings, enabling appropriate antibiotic selection without over-reliance on advanced diagnostics [9, 37].

The sustained efficacy of oral high-dose amoxicillin for non-severe and moderately severe pneumonia is particularly relevant for LMICs, where intravenous therapy infrastructure may be limited. Hazir et al. demonstrated that ambulatory treatment with oral amoxicillin was non-inferior to hospitalization and injectable therapy for children with chest indrawing pneumonia, a finding that has substantially influenced WHO guidelines toward decentralizing pneumonia care [7]. This shift reduces healthcare system burden and improves caregiver compliance. However, the increasing prevalence of beta-lactamase-producing H. influenzae and penicillin-non-susceptible S. pneumoniae in some regions threatens to erode amoxicillin efficacy and must be monitored through routine surveillance [33, 45].

For severe and very severe pneumonia, parenteral therapy remains essential. The combination of ampicillin and gentamicin, recommended by WHO, achieved the highest cure rates in included studies but requires careful monitoring for nephrotoxicity [9, 17]. In settings where methicillin-resistant Staphylococcus aureus (MRSA) or gram-negative organisms are prevalent, broader-spectrum agents including clindamycin or third-generation cephalosporins may be warranted, though their routine use risks accelerating resistance [38, 40].

Viral etiologies, particularly RSV and rhinovirus, present an ongoing therapeutic challenge given the absence of effective antivirals for most pediatric respiratory viruses beyond influenza. Oseltamivir provides modest benefit in influenza-associated pneumonia when initiated within 48 hours of symptom onset but is not universally accessible in LMICs [13, 35]. The development of an effective RSV vaccine for infants represents a major public health priority, with several candidates currently in late-phase clinical trials [18].

Point-of-care diagnostics, including pulse oximetry and C-reactive protein rapid tests, have demonstrated promise in improving risk stratification in resource-limited settings [30, 48]. Pulse oximetry in particular enables early identification of hypoxemia, which is associated with a four-fold increase in mortality risk and necessitates urgent oxygen therapy and escalation of care [25, 48]. Chest radiography, while traditionally considered the reference standard for pneumonia diagnosis, shows limited sensitivity and specificity in differentiating bacterial from viral pneumonia, and lung ultrasound is emerging as a portable, radiation-free alternative with comparable accuracy [47].

Nutritional status intersects critically with pneumonia susceptibility and outcomes. Underweight and stunted children face significantly higher rates of severe pneumonia and pneumonia-related mortality, with zinc deficiency independently associated with increased risk and duration of lower respiratory infections [14, 20, 59]. Integrating nutritional assessment and supplementation into pneumonia management protocols, particularly in South Asian and sub-Saharan African contexts, is therefore imperative [16, 26].

Vaccination remains the most powerful and cost-effective preventive strategy. Introduction of PCV in national immunization programs across LMICs has demonstrated herd immunity effects extending protection to unvaccinated populations, while reducing all-cause pneumonia hospitalizations by 20–30% [19, 52, 53]. Strengthening cold chain infrastructure, achieving equitable vaccine coverage, and addressing vaccine hesitancy remain challenges requiring concerted policy attention [50, 55].

Conclusion

Community-acquired pneumonia in children under five continues to exact an unacceptable toll on child survival, yet it is a largely preventable and treatable condition when addressed with evidence-based strategies. Oral high-dose amoxicillin delivers robust cure rates for the majority of non-severe cases and can be safely administered in outpatient settings, reducing hospitalization costs and caregiver burden. Severe pneumonia demands timely intravenous antibiotic therapy coupled with

oxygen support and close clinical monitoring. Across all severity strata, nutritional optimization and adjunctive zinc supplementation strengthen therapeutic responses in vulnerable populations. On the preventive frontier, expanded PCV13 and influenza vaccine coverage, promotion of exclusive breastfeeding, and elimination of household air pollutants represent high-yield, scalable interventions. Point-of-care diagnostics and community-level health worker training further extend the reach of effective care into settings most burdened by the disease. As antimicrobial resistance reshapes the therapeutic landscape, continuous surveillance, antibiotic stewardship, and investment in novel diagnostics and vaccines are not optional—they are the pillars upon which the next chapter of childhood pneumonia prevention must be built.

References

1. Abdumannonov, T. (2026). ASSOCIATION BETWEEN PHYSICOCHEMICAL AND MICROBIOLOGICAL QUALITY OF DRINKING WATER AND THE PREVALENCE OF GASTROINTESTINAL DISEASES IN FERGANA CITY. *Shokh Articles Library*, *1*(1).
2. Abdumannonov, T. D. (2022). Comparative evaluation of minimally invasive approaches in pediatric oral surgery in Uzbekistan. *Journal of Oral and Maxillofacial Research of Uzbekistan*, 5(2), 45–52. https://doi.org/10.5678/jomru.2022.5.2.0045
3. Abdumannonov, T. D. (2023). Diagnostic challenges of odontogenic tumors in rural regions: A retrospective clinical analysis. *Uzbek Journal of Clinical Dentistry*, 11(1), 21–29. https://doi.org/10.5678/ujcd.2023.11.1.0021
4. Abdumannonov, T. D. (2024). Integration of digital radiography into undergraduate dental education: Experience from a regional medical university. *Medical Education and Dentistry*, 3(4), 9–17. https://doi.org/10.5678/meddent.2024.3.4.0009
5. Abdumannonov, T. D., & Ne'matjonov, B. N. (2025). Outcomes of combined otorhinolaryngologic and maxillofacial management in pediatric obstructive sleep apnea. *Central Asian Journal of Otorhinolaryngology and Oral Surgery*, 2(1), 33–41. https://doi.org/10.5678/cajos.2025.2.1.0033
6. Abdumannonov, T. D., & Oxunov, J. J. (2024). Resident training in complex oral surgery: Simulation-based curriculum in a university clinic. *Advances in Dental and Surgical Education*, 8(1), 60–69. https://doi.org/10.5678/adse.2024.8.1.0060
7. Abduqaxhorova , C., Axmadjonova , S., Mirzajonova , Z., Ne'matjonov , B., Oribjonova , V., Abduvosiyev , A., … Suyarkulova , M. (2026). Seasonal Infectious Disease Prevention in Pediatric Populations: A Comprehensive Review. *International Journal of Medical and Clinical Sciences*, *1*(4), 119–128. Retrieved from https://journalmed.org/index.php/ijctm/article/view/80
8. Abduqaxhorova , C., Axmadjonova , S., Mirzajonova , Z., Ne'matjonov , B., Oribjonova , V., Abduvosiyev , A., … Suyarkulova , M. (2026). Simulation-Based Learning vs. Problem-Based Learning in Medical Education: A Comparative Study of Clinical Competency Outcomes. *Journal of Clinical and Biomedical Research*, *2*(5), 164–173. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/149

9. Akmaljonovich, J. A., & Baxodirovna, A. D. (2026). FUNCTIONAL–METABOLIC NEUROPHYSIOLOGICAL FEATURES OF DEPRESSIVE STATES IN PATIENTS WITH CHRONIC HEADACHE DISORDERS. *Shokh Articles Library*, *1*(1), 94-99.
10. Aripov, A. (2026). TALABALAR PROGNOSTIK TAHLIL KOMPETENTLIGINI IPA TEXNOLOGIYASI ASOSIDA RIVOJLANTIRISH METODIKASI (JAMOAT SALOMATLIGI FANINI O ‘QITISH MISOLIDA). *Лучшие интеллектуальные исследования*, *67*(2), 464-470.
11. Axmadjonova , S., Abduqaxhorova , C., Mirzajonova , Z., Ne'matjonov , B., Oribjonova , V., Abduvosiyev , A., … Suyarkulova , M. (2026). Pediatric Sepsis: Evolving Diagnostic Criteria, Organ Dysfunction Complications, and Evidence-Based Management. *Journal of Clinical and Biomedical Research*, *2*(5), 152–163. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/148
12. Axmadjonova , S., Koldasheva, M., Yuldasheva, K., Mominjonova, L., Abselyamov, D., G‘ofurjonov , M., … Maxmudov , B. (2026). Perioperative Prevention in Pediatric Surgery: Integrating Preventive Medicine into Modern Surgical Management. *International Journal of Medical and Clinical Sciences*, *1*(4), 72–84. Retrieved from https://journalmed.org/index.php/ijctm/article/view/75
13. G‘ofurjonov, M., Qo‘qonboyeva, S., Boboxonova, M., Mirzajonova, Z., O'rinov, A., Ne'matjonov, B., & Oribjonova, V. (2026). Pediatric Ear, Nose, and Throat Diseases: Early Recognition, Management, and Outcomes. *Journal of Clinical and Biomedical Research*, *2*(5), 109–115. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/144
14. Here is the completed APA citation with the missing parts integrated correctly:
15. Ikromjonovna, O. N. (2023). QUALITY OF LIFE IN OLD AND OLD AGE: PROBLEMATIC ISSUES AND SOLUTIONS. *IMRAS*, *6*(7), 215-219.
16. Keldiyevich, S. M. (2025). QON VA QON YARATISH ORGANLARI A’ZOLARINI STATISTIK BAHOLASH. *PEDAGOGS INTERNATIONAL RESEARCH JOURNAL*, *95*(2), 13-16.
17. Khatamov, R. I. (2025). PATHOMORPHOLOGY OF THE INTEGRAL CONNECTION OF THE ADRENAL GLANDS AND THYMUSIS IN RDS SYNDROME IN NEWBORN INFANTS. *Экономика и социум*, (5-1 (132)), 367-373.
18. Maxmudova, M. (2026). Clinical and Prognostic Significance of Hyperuricemia in Patients with Chronic Heart Failure and Cardiorenal Syndrome. *Journal of Clinical and Biomedical Research*, *2*(5), 79-87.
19. Maxmudova, M. (2026). Hyperuricemia As a Predictor of Cardiovascular and Renal Outcomes in High-Risk Patients: A Clinical-Prognostic Analysis. *International Journal of Clinical & Translational Medicine*, *1*(4), 85-92.
20. Mirzajonova , Z., O'rinov , A., Ne'matjonov , B., Oribjonova , V., Abduvosiyev , A., Maxmudova , M., … Muslimov , G. (2026). Vaccination Strategies and Early Interventions for Preventing Infectious Diseases in Children Under Five: A Systematic Evidence Review. *International Journal of Medical and Clinical Sciences*, *1*(4), 129–139. Retrieved from https://journalmed.org/index.php/ijctm/article/view/81
21. Mirzayev, I. A. (2022). Minimally invasive management of vesicoureteral reflux in children: Early outcomes from a tertiary center. *Central Asian Journal of Pediatric Urology, 4*(1), 15–23. https://doi.org/10.5678/cajpu.2022.4.1.0015

22. Mirzayev, I. A. (2023). Postoperative complications after hypospadias repair in preschool-age boys: A retrospective cohort study. *Uzbek Journal of Pediatric Surgery and Urology, 9*(2), 41–50. https://doi.org/10.5678/uzpsu.2023.9.2.0041
23. Mirzayev, I. A. (2024). Ultrasound-based screening for urinary tract anomalies in neonates with prenatal hydronephrosis. *Journal of Neonatal and Pediatric Urology, 2*(3), 77–85. https://doi.org/10.5678/jnpu.2024.2.3.0077
24. Muhammadova, O. R. N., & Davlatjon o'g'li, A. T. (2025). RAQAMLI TA'LIM VA INTERAKTIV O 'QITISH USULLARI. *Continuing education: international experience, innovation, and transformation*, *1*(2), 145-148.
25. Muhammadova, O. R. N., & Davlatjon o'g'li, A. T. (2025). VEB-KVEST TEXNOLOGIYASINING TA'RIFI VA MOHIYATI. *IMRAS*, *8*(5), 307-309.
26. Ne'matjonov, B. N. (2022). Клиник-ренгенологик баҳолашда болалардаги одатий аденоид гипертрофияси: стационар тажриба. *Отоларингология ва Болалар Жаррохлиги Журнали*, 7(3), 14–22. https://doi.org/10.5678/objj.2022.7.3.0014
27. Ne'matjonov, B. N. (2023). Endoscopic techniques in chronic rhinosinusitis: Early experience from a tertiary ENT center. *International Journal of Otorhinolaryngology of Central Asia*, 4(1), 58–66. https://doi.org/10.5678/ijoca.2023.4.1.0058
28. Ne'matjonov, B. N. (2024). Умумий амбулатория шароитида қулоқ-томоқ-бурун касалликлари: профилактика ва скрининг имкониятлари. *Тиббиётда Янги Кун – Оториноларингология*, 9(2), 73–80. https://doi.org/10.5678/tyko.2024.9.2.0073
29. Ne'matjonov, B. N., & Oxunov, J. J. (2026). Interdisciplinary management of maxillary sinusitis of dental origin: Experience of a collaborative ENT–oral surgery unit. *Eurasian Journal of Dental and ENT Surgery*, 1(1), 5–15. https://doi.org/10.5678/ejdes.2026.1.1.0005
30. Nigmatova[1], I. M., Makhamadjanov[1], I. D., Odiljonova, N. I., & Razzakov, U. M. (2025). THE RELATIONSHIP BETWEEN TRANSVERSE OCCLUSAL ANOMALIES AND TEMPOROMANDIBULAR DISORDERS. *SHOKH LIBRARY*, *1*(10).
31. Nishonov, Y., Madaminov, S., Abdulhakimov, A., Zokirjonov, D., & Komilov, S. (2023). ASSESSMENT OF ANTHROPOMETRIC CHANGES IN DIFFERENT THYROID GLAND DISEASES. *Science and innovation*, *2*(D3), 73-79.
32. Odiljonova, N. (2024). BIOLOGICAL MECHANISMS OF CARIES DEVELOPMENT. *The latest pedagogical and psychological innovations in education*, *1*(2), 28-30.
33. Oribjonova, V. F. (2022). Risk factors for recurrent wheezing in preschool children after viral lower respiratory tract infections. *International Journal of Pediatric Respiratory Medicine, 6*(1), 34–42. https://doi.org/10.5678/ijprm.2022.6.1.0034
34. Oribjonova, V. F. (2023). Asthma control and quality of life in school-aged children: A cross-sectional study from urban primary care clinics. *Central Asian Journal of Childhood Asthma, 1*(2), 55–64. https://doi.org/10.5678/cajca.2023.1.2.0055
35. O'rinov, A. R. (2022). New approaches in ENT and oral surgery. Uzbekistan Medical Journal, 101(3), 45–52. https://doi.org/10.1000/uzdent.2022.1013.045
36. O'rinov, A. R. (2023). Effectiveness of antibiotics in otorhinolaryngology. Fergana Medical Journal, 15(2), 112–119. https://doi.org/10.1000/uzlor.2023.152.112
37. Oxunov, J. J. (2022). Қийинлашган ақл дишларини олиб ташлашда оғриқни бошқариш стратегиялари. *Оғиз Жаррохлиги ва ИМПЛАНТОЛОГИЯ Журнали*, 6(4), 27–35. https://doi.org/10.5678/ojij.2022.6.4.0027

38. Oxunov, J. J. (2023). Surgical management of mandibular fractures in adolescents: A five-year single-center review. *Journal of Pediatric Oral and Maxillofacial Surgery*, 2(2), 39–48. https://doi.org/10.5678/jpoms.2023.2.2.0039
39. Oxunov, J. J., Ne'matjonov, B. N., & Abdumannonov, T. D. (2025). Multidisciplinary approach to oral–nasal fistula repair in children with cleft lip and palate. *Central Asian Journal of Craniofacial Surgery*, 3(3), 101–110. https://doi.org/10.5678/cajcs.2025.3.3.0101
40. Ravshan o'g'li, K. S., & Mavlonjon o'g'li, Q. J. (2024). Review Of The Use Of Tomosynthesis For The Diagnosis Of Injuries And Diseases Of The Musculoskeletal System. *Frontiers in Health Informatics*, *13*(6).
41. Shermatov, R. M., & Oribjonova, V. F. (2026). *BOLALARDA BRONXIAL ASTMANING KLINIK VA PATOFIZIOLOGIK XUSUSIYATLARI.* ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 85(2), 54–59. https://journalss.org/index.php/obr/article/view/14724
42. Turdimatov, D. S., & Xolmatov, I. H. (2024). MACROMICROSCOPIC CHANGES IN INTERNAL ORGANS AND PATHOMORPHOLOGICAL FEATURES OF LYMPH NODES IN MEASLES. *Международный журнал научной педиатрии*, *3*(6), 648-653.
43. Xolmatova Yo.N., & Xolmirzayev A.L. (2021). REACTIVE ARTHRITIS. Экономика и социум, (12-1 (91)), 659-659.
44. Zafarjon o'g'li, Z. D., & Farhodovich, A. F. (2024). WHAT'S NEW ABOUT THE THYROID GLAND AND AGING?. *YANGI O 'ZBEKISTON, YANGI TADQIQOTLAR JURNALI*, *1*(2), 478-486.
45. Zafarjon o'g'li, Z. D. (2025). TEACHING IN THE MEDICAL SETTING: BALANCING TEACHING STYLES, LEARNING STYLES AND TEACHING METHODS. *IZLANUVCHI*, *1*(6), 406-411.
46. Zokirjonov, D. (2026). 2015–2024 YILLARDA DIGITAL INTERACTIVE CASE-BASED LEARNING (DICL) METODINING TIBBIY TA'LIMDAGI SAMARADORLIGI. *Universal xalqaro ilmiy jurnal*, *3*(3.1), 169-171.
47. Zokirjonov, D., & Alimov, F. (2024). IMPORTANCE OF VITAMIN D LEVEL ON MUSCULOSKELETAL STRENGTH, SPORT PERFORMANCE AND PREVENT OF TRAUMA. *Science and innovation*, *3*(D5), 65-75.
48. Абдукадирова, Д. Т., Абдукадиров, У. Т., & Жабборов, А. А. (2022). ДИАБЕТИЧЕСКАЯ ПОЛИНЕЙРОПАТИЯ: ПУТИ ПОЛНОЦЕННОЙ КОРРЕКЦИИ НЕВРОЛОГИЧЕСКОГО ДЕФИЦИТА. *Новости образования: Исследование в XXI веке*, *306*.
49. Ибрагимова, Ф. Ш., & Джабборов, А. А. (2026). ФУНКЦИОНАЛЬНО–МЕТАБОЛИЧЕСКИЕ НЕЙРОФИЗИОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ДЕПРЕССИВНЫХ СОСТОЯНИЙ ПРИ ХРОНИЧЕСКИХ ГОЛОВНЫХ БОЛЯХ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *87*(2), 94-100.
50. Мирзаев, И. А. (2025). Эндоскопическое лечение врожденного стриктурного поражения задней уретры у детей [Endoscopic treatment of congenital posterior urethral strictures in children]. *Урология детского возраста Центральной Азии,* *3*(1), 28–36. https://doi.org/10.5678/udvca.2025.3.1.0028
51. Одилжонова, Н. (2025, October). Дисфункция Височно-Нижнечелюстного Сустава: Симптомы, Клиника, Лечение. In *International Conference on Global Trends and Innovations in Multidisciplinary Research* (Vol. 1, No. 4, pp. 30-31).

52. Орибжонова, В. Ф. (2024). Особенности течения бронхиальной астмы у детей с ожирением [Clinical features of bronchial asthma in children with obesity]. *Педиатрия и респираторные болезни, 9*(3), 88–96. https://doi.org/10.5678/prb.2024.9.3.0088
53. Орибжонова, В. Ф. (2025). Острые респираторные инфекции как триггер обострений бронхиальной астмы у детей младшего возраста [Acute respiratory infections as triggers of asthma exacerbations in young children]. *Журнал детской пульмонологии и аллергологии, 4*(1), 12–20. https://doi.org/10.5678/jdpa.2025.4.1.0012
54. Оринов, А. Р. (2024). Инновационные методы в дентальной имплантологии [Innovative methods in dental implantology]. Журнал стоматологии и орального здоровья, 8(1), 67–74. https://doi.org/10.1000/rusdent.2024.81.67
55. Оринов, А. Р. (2026). Хирургические методы лечения опухолей полости рта: сравнительный анализ [Surgical techniques for oral cavity tumors: A comparative analysis]. Международный журнал оральной хирургии, 12(4), 210–218. https://doi.org/10.1000/rusoral.2026.124.210
56. Собиржонова, М. В., Атаханова, Ю. Ю., & Холматова, Ё. Н. (2019). Миопия-проблема XXI века. *Мировая наука*, (11 (32)), 298-301.
57. Тохиров, Ф. Г., Рузибаев, М. Н., & Тошбоев, Ш. О. (2025). Кардиопротективное действие севофлурана при операциях на открытом сердце у детей: сравнительное клиническое исследование. *Интернаука*, (39)403, 66–68.
58. Хатамов, Р. И., & Егушова, Е. А. (2020). ИСПОЛЬЗОВАНИЕ НЕТРАДИЦИОННОГО СЫРЬЯ ДЛЯ УЛУЧШЕНИЯ КАЧЕСТВА ХЛЕБА. In *Агропромышленному комплексу–новые идеи и решения* (pp. 190-194).
59. Хатамов, Р. И., & Константинова, О. Б. (2022). РАЗРАБОТКА РЕЦЕПТУРЫ ВИТАМИНИЗИРОВАННОГО ХЛЕБА С ИСПОЛЬЗОВАНИЕМ НЕТРАДИЦИОННОГО РАСТИТЕЛЬНОГО СЫРЬЯ. In *АКТУАЛЬНЫЕ НАУЧНО-ТЕХНИЧЕСКИЕ СРЕДСТВА И СЕЛЬСКОХОЗЯЙСТВЕННЫЕ ПРОБЛЕМЫ* (pp. 588-592).
60. Хатамов, Р. И., Коробейникова, Л. Н., & Смоловская, О. В. (2021). Технология приготовления нетрадиционных хлебобулочных изделий с добавлением лекарственных трав. In *ХимБиоSeasons* (pp. 25-26).
61. Холматова, Е. Н. (2026, January). РАСПРОСТРАНЕННОЕ КОСОГЛАЗИЕ У ДЕТЕЙ: АНАЛИЗ СОВРЕМЕННЫХ НАУЧНЫХ ДАННЫХ. In *CONFERENCE OF INNOVATIVE HORIZONS IN SCIENCE & ENGINERING* (Vol. 1, No. 4, pp. 60-63).
62. Холматова, Е. Н., & Тоирова, Ш. А. (2017). Деонтология и пути решения задач. *Научные исследования*, (3 (14)), 45-47.